Avidity Biosciences Inc(RNAM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.96 | Insider Own | 5.98% | Shs Outstand | 151.2M | Perf Week | - |
| Market Cap | 11.30B | Forward P/E | - | EPS next Y | -16.28% | Insider Trans | - | Shs Float | 145.9M | Perf Month | -0.14% |
| Enterprise Value | 9.65B | PEG | - | EPS next Q | -1.36 | Inst Own | 92.11% | Short Float | 6.18% | Perf Quarter | 2.06% |
| Income | -0.68B | P/S | 602.56 | EPS this Y | -54.81% | Inst Trans | - | Short Ratio | 3.34 | Perf Half Y | 77.44% |
| Sales | 0.02B | P/B | 6.52 | EPS next 5Y | -10.16% | ROA | -38.88% | Short Interest | 9.01M | Perf YTD | 0.96% |
| Book/sh | 11.17 | P/C | 6.66 | EPS past 3/5Y | -14.23% -19.41% | ROE | -43.98% | 52W High | -0.33% ($73.06) | Perf Year | 145.6% |
| Cash/sh | 10.94 | P/FCF | - | Sales past 3/5Y | 26.69% 22.54% | ROIC | -39.48% | 52W Low | 238.54% ($21.51) | Perf 3Y | 219.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -71.19% | Gross Margin | 77.87% | Volatility(W/M) | 0.33% 0.31% | Perf 5Y | 201.78% |
| Dividend TTM | - | EV/Sales | 514.69 | Sales Y/Y TTM | 72.11% | Oper. Margin | -3977.3% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.2 | EPS Q/Q | -99.6% | Profit Margin | -3650.39% | RSI (14) | 58.41 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.2 | Sales Q/Q | -71.07% | SMA20 | 0% ($72.82) | Beta | 0.98 | Target Price | $72.67 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 11000000 | SMA50 | 0.42% ($72.52) | Rel Volume | 0 | Prev Close | $72.82 |
| Employees | 511 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -17.02% 545.33% | SMA200 | 38.23% ($52.68) | Avg Volume(3M) | 2.70M | Price | $72.82 |
| IPO | 2020/6/12 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧬 RNA therapeutics developer focused on treatments for muscular dystrophy. Three late-stage clinical pipelines targeting DMD, DM1, and FSHD. Pursuing strategic integration following its acquisition by Novartis (2026).
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
RNAM has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -54.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $60,256. Peers typically go for $192.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +201.8%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 92.1%.
Tap to view numbers
It ranks #21 of 598 in the industry
Based on market cap of $11B.
HALO#19 Halozyme Therapeutics Inc $12B PER 26.4 
TECH#20 Bio-Techne Corp $11B PER 62.9 RNAM#21 Avidity Biosciences Inc $11B PER - 
KYMR#21 Kymera Therapeutics Inc $11B PER - 
BMRN#22 Biomarin Pharmaceutical Inc $11B PER - 
FAQ
What kind of company is RNAM?
RNAM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNAM?
The market cap of RNAM is approximately $11.3B, ranking 839 within its sector.
What is the 52-week high and low for RNAM?
RNAM has recorded a 52-week high of $73.06 and a low of $21.51.
